Levofloxacin Kabi (Levofloxacin Hemihydrate)

Levofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for DNA replication and transcription. This inhibition prevents bacterial cells from replicating their DNA, leading to bactericidal activity against a broad range of Gram‑positive and Gram‑negative organisms.

The prescribed dose of Levofloxacin Kabi is determined by the treating physician based on the type and severity of the infection, the patient’s renal function, body weight, and any relevant comorbidities. Dosage adjustments may be required for patients with impaired kidney function.

Levofloxacin is classified as pregnancy category unknown; it should only be used during pregnancy or lactation when the potential benefits justify the potential risks to the fetus or infant. Clinicians typically consider alternative agents with established safety profiles for pregnant or nursing patients.

To order Levofloxacin Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and assist with import documentation.

Levofloxacin is the L‑isomer of ofloxacin and generally offers higher potency, broader spectrum coverage, and better tissue penetration than many older fluoroquinolones. Compared with ciprofloxacin, it has enhanced activity against Gram‑positive organisms and requires once‑daily dosing for many indications, which can simplify treatment regimens.

Levofloxacin Kabi should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If the solution is reconstituted, follow the manufacturer’s guidance on stability and discard any unused portion after the specified time.

Levofloxacin Kabi is administered intravenously by slow infusion, typically over 30‑60 minutes, under the supervision of a qualified healthcare professional. The exact infusion rate and duration are determined by the prescribing clinician based on the patient’s condition and the specific dosing regimen.

Serious risks include tendon rupture or tendinitis, especially in older adults; QT interval prolongation leading to potentially life‑threatening arrhythmias; severe allergic reactions such as anaphylaxis; Clostridioides difficile‑associated colitis; hepatic injury; and central nervous system effects like seizures. Prompt medical attention is required if any of these events occur.

Levofloxacin Kabi should be avoided in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, patients with significant QT prolongation, and individuals receiving concomitant medications that markedly increase the risk of serious cardiac or tendon complications.